Neelesh K Nadkarni1,2, Dana Tudorascu3,4,5, Elizabeth Campbell6, Beth E Snitz2, Annie D Cohen5, Edye Halligan5, Chester A Mathis6, Howard J Aizenstein5, William E Klunk2,5. 1. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pennsylvania. 2. Department of Neurology, University of Pittsburgh, Pennsylvania. 3. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pennsylvania. 4. Department of Biostatistics, University of Pittsburgh, Pennsylvania. 5. Department of Psychiatry, University of Pittsburgh, Pennsylvania. 6. Department of Radiology, University of Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: We estimated the prevalence and incidence of amyloid-β deposition (A), small-vessel disease (V), and neurodegeneration (N) biomarker positivity in community-dwelling cognitively normal individuals (CN). We determined the longitudinal association between the respective biomarker indices with progression to all-cause mild cognitive impairment (MCI) and its amnestic and nonamnestic subtypes. METHODS: CN participants, recruited by advertising, underwent brain [C-11]Pittsburgh Compound-B (PiB)-positron emission tomography (PET), magnetic resonance imaging, and [F-18]fluoro-2-deoxy-glucose (FDG)-PET, and were designated as having high or low amyloid-β (A+/A-), greater or lower white matter hyperintensities burden (V+/V-) and diminished or normal cortical glucose metabolism (N+/N-). MCI was adjudicated using clinical assessments. We examined the association between A, V, and N biomarker positivity at study baseline and endpoint, with progression to MCI using linear regression, Cox proportional hazards and Kaplan-Meier analyses adjusted for age and APOE-ε4 carrier status. RESULTS: In 98 CN individuals (average age 74 years, 65% female), A+, V+, and N+ prevalence was 26%, 33%, and 8%, respectively. At study endpoint (median: 5.5 years), an A+, but not a V+ or N+ scan, was associated with higher odds of all-cause MCI (Chi-square = 3.9, p = .048, odds ratio, 95% confidence interval = 2.6 [1.01-6.8]). Baseline A+, V+, or N+ were not associated with all-cause MCI, however, baseline A+ (p = .018) and A+N+ (p = .049), and endpoint A+N+ (p = .025) were associated with time to progression to amnestic, not nonamnestic, MCI. CONCLUSION: Longitudinal assessments clarify the association between amyloid-β and progression to all-cause MCI in CN individuals. The association between biomarker positivity indices of amyloid-β and neurodegeneration, and amnestic MCI reflects the underlying pathology involved in the progression to prodromal Alzheimer's disease.
BACKGROUND: We estimated the prevalence and incidence of amyloid-β deposition (A), small-vessel disease (V), and neurodegeneration (N) biomarker positivity in community-dwelling cognitively normal individuals (CN). We determined the longitudinal association between the respective biomarker indices with progression to all-cause mild cognitive impairment (MCI) and its amnestic and nonamnestic subtypes. METHODS: CN participants, recruited by advertising, underwent brain [C-11]Pittsburgh Compound-B (PiB)-positron emission tomography (PET), magnetic resonance imaging, and [F-18]fluoro-2-deoxy-glucose (FDG)-PET, and were designated as having high or low amyloid-β (A+/A-), greater or lower white matter hyperintensities burden (V+/V-) and diminished or normal cortical glucose metabolism (N+/N-). MCI was adjudicated using clinical assessments. We examined the association between A, V, and N biomarker positivity at study baseline and endpoint, with progression to MCI using linear regression, Cox proportional hazards and Kaplan-Meier analyses adjusted for age and APOE-ε4 carrier status. RESULTS: In 98 CN individuals (average age 74 years, 65% female), A+, V+, and N+ prevalence was 26%, 33%, and 8%, respectively. At study endpoint (median: 5.5 years), an A+, but not a V+ or N+ scan, was associated with higher odds of all-cause MCI (Chi-square = 3.9, p = .048, odds ratio, 95% confidence interval = 2.6 [1.01-6.8]). Baseline A+, V+, or N+ were not associated with all-cause MCI, however, baseline A+ (p = .018) and A+N+ (p = .049), and endpoint A+N+ (p = .025) were associated with time to progression to amnestic, not nonamnestic, MCI. CONCLUSION: Longitudinal assessments clarify the association between amyloid-β and progression to all-cause MCI in CN individuals. The association between biomarker positivity indices of amyloid-β and neurodegeneration, and amnestic MCI reflects the underlying pathology involved in the progression to prodromal Alzheimer's disease.
Authors: V L Villemagne; K E Pike; D Darby; P Maruff; G Savage; S Ng; U Ackermann; T F Cowie; J Currie; S G Chan; G Jones; H Tochon-Danguy; G O'Keefe; C L Masters; C C Rowe Journal: Neuropsychologia Date: 2008-02-14 Impact factor: 3.139
Authors: W T Longstreth; T A Manolio; A Arnold; G L Burke; N Bryan; C A Jungreis; P L Enright; D O'Leary; L Fried Journal: Stroke Date: 1996-08 Impact factor: 7.914
Authors: Adam M Brickman; Frank A Provenzano; Jordan Muraskin; Jennifer J Manly; Sonja Blum; Zoltan Apa; Yaakov Stern; Truman R Brown; José A Luchsinger; Richard Mayeux Journal: Arch Neurol Date: 2012-12
Authors: Oscar L Lopez; William E Klunk; Chester Mathis; Rhaven L Coleman; Julie Price; James T Becker; Howard J Aizenstein; Beth Snitz; Ann Cohen; Milos Ikonomovic; Eric McDade; Steven T DeKosky; Lisa Weissfeld; Lewis H Kuller Journal: Neurology Date: 2014-10-10 Impact factor: 9.910
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; David S Knopman; Val Lowe; Prashanthi Vemuri; Michelle M Mielke; David T Jones; Matthew L Senjem; Jeffrey L Gunter; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen Journal: Neurology Date: 2013-10-16 Impact factor: 9.910
Authors: Rosebud O Roberts; Jeremiah A Aakre; Walter K Kremers; Maria Vassilaki; David S Knopman; Michelle M Mielke; Rabe Alhurani; Yonas E Geda; Mary M Machulda; Preciosa Coloma; Barbara Schauble; Val J Lowe; Clifford R Jack; Ronald C Petersen Journal: JAMA Neurol Date: 2018-08-01 Impact factor: 18.302
Authors: Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk Journal: Arch Neurol Date: 2008-11
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu Journal: Neurobiol Aging Date: 2020-05-31 Impact factor: 4.673
Authors: T Ding; A D Cohen; E E O'Connor; H T Karim; A Crainiceanu; J Muschelli; O Lopez; W E Klunk; H J Aizenstein; R Krafty; C M Crainiceanu; D L Tudorascu Journal: Neuroimage Clin Date: 2019-12-27 Impact factor: 4.881
Authors: Ramon Casanova; Fang-Chi Hsu; Ryan T Barnard; Andrea M Anderson; Rajesh Talluri; Christopher T Whitlow; Timothy M Hughes; Michael Griswold; Kathleen M Hayden; Rebecca F Gottesman; Lynne E Wagenknecht Journal: Alzheimers Dement Date: 2021-07-26 Impact factor: 16.655
Authors: Kevin J Sullivan; Anran Liu; Chung-Chou H Chang; Ann D Cohen; Brian J Lopresti; Davneet S Minhas; Charles M Laymon; William E Klunk; Howard Aizenstein; Neelesh K Nadkarni; David Loewenstein; M Ilyas Kamboh; Mary Ganguli; Beth E Snitz Journal: Brain Imaging Behav Date: 2020-08-03 Impact factor: 3.224